Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Key claim: Ocugen reports provisional approval and priority designation in The Bahamas under the Longevity and Regenerative Therapies Act to provide OCU400 gene therapy for retinitis pigmentosa.
Abstract
News coverage by ir.ocugen.com: “Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa”. Headline and link only — this finding reports press coverage of a government action, not the primary record.
Why this matters
Ocugen reports provisional approval and priority designation in The Bahamas under the Longevity and Regenerative Therapies Act to provide OCU400 gene therapy for retinitis pigmentosa.